RAJINDERPAL SINGH: Open Payments
NPI 1548420813 · RICHMOND, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$397 in 15 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $25 · 2025 $397
Food & beverage: $397
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $80 |
| Vanda Pharmaceuticals Inc. | 2 | $68 |
| E.R. Squibb & Sons, L.L.C. | 2 | $52 |
| Alkermes, Inc. | 2 | $51 |
| Janssen Pharmaceuticals, Inc | 1 | $31 |
| Neurocrine BioSciences, Inc. | 1 | $27 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| ABBVIE INC. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
Products named: CAPLYTA, FANAPT, COBENFY, ARISTADA, INVEGA SUSTENNA, INGREZZA, Auvelity, UZEDY.
Industry payments across VA — which companies pay providers there.
